Figure 4 | Scientific Reports

Figure 4

From: Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan

Figure 4

ADCC results (mean ± SEM) of sacituzumab govitecan, ADC isotype control, hRS7 IgG and Rituximab (anti-CD20) in two representative cervical cancer cell lines (ie, CVX8 2 + Trop-2 positive cell line vs ADX2 Trop-2 negative cell line). Significant ADCC was detectable only against the Trop-2 positive tumors.

Back to article page